GCP
PSTX

GSA Capital Partners’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

GSA Capital Partners’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-74,040
Closed -$130K – 2003
2023
Q2 		$130K Buy
74,040
+20,641
+39% +$52.7K 0.01% 1359
2023
Q1 		$164K Sell
53,399
-42,070
-44% -$252K 0.02% 1292
2022
Q4 		$506K Buy
+95,469
New +$436K 0.06% 594
2022
Q1 		– Sell
-84,701
Closed -$577K – 1921
2021
Q4 		$577K Buy
+84,701
New +$577K 0.07% 515

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

GSA Capital Partners's PSTX Position: Q3 2023 in Review

GSA Capital Partners sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q3 2023, closing a stake of 74,040 shares — an estimated $130K sold.

GSA Capital Partners first reported a position in PSTX in Q4 2021 and held it in 4 quarters. The position peaked at $577K in Q4 2021. 86 funds tracked by Wall St. Rank hold PSTX as of Q3 2023.

  • GSA Capital Partners reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • GSA Capital Partners sold 74,040 Poseida Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $130K.
  • GSA Capital Partners first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
  • GSA Capital Partners's Poseida Therapeutics, Inc. Common Stock position peaked at $577K in Q4 2021.
  • 86 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q3 2023.

Based on GSA Capital Partners's 13F filing for Q3 2023, filed 15 Nov 2023.